The recent editorial in the journal Science, authored by Luc L. Hagenaars from the University of Amsterdam and Laura A. Schmidt from the University of California, discusses the rising prominence of GLP-1 agonists, particularly Ozempic. They have labeled this phenomenon “the Ozempic era,” noting its widespread impact across scientific, clinical, and public spheres.
Initially designed for diabetes treatment, GLP-1 agonists are now being used for a broader range of conditions—including skin issues, erectile dysfunction, fertility problems, and even addictions. While the authors acknowledge benefits, such as reduced cravings for unhealthy foods and a framework from the WHO for equitable access, they raise concerns over potential social inequalities and a skewed understanding of obesity as largely an individual issue.
Pharmaceutical giants like Eli Lilly and Novo Nordisk frame obesity as a chronic condition, which reinforces individual-focused solutions. This perspective is echoed by wellness platforms and the food industry, all vying for a share of the market while promoting a narrative that prioritizes profit over public health.
The authors advocate for WHO intervention to ensure that the use of GLP-1 drugs contributes positively to health equity rather than exacerbating existing disparities.
